Regulation of FAK Ser-722 phosphorylation and kinase activity by GSK3 and PP1 during cell spreading and migration
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
In addition to tyrosine sites, FAK (focal adhesion kinase) is phosphorylated on multiple serine residues. In the present study, the regulation of two of these sites, Ser-722 (S1) and Ser-911 (S4), was investigated. Phosphorylation of S1 (but not S4) decreased in resuspended cells, and recovered during spreading on fibronectin, indicating adhesion-dependent regulation. GSK3 (glycogen synthase kinase 3) inhibitors decreased S1 phosphorylation, and siRNA (short interfering RNA) silencing indicated further the involvement of GSK3β. Furthermore, GSK3β was found to become activated during cell spreading on fibronectin, and to physically associate with FAK. S1 phosphorylation was observed to decrease in wounded cell monolayers, while GSK3β underwent inactivation and later was observed to increase to the original level within 24 h. Direct phosphorylation of S1, requiring pre-phosphorylation of Ser-726 in the +4 position, was demonstrated using purified GSK3 and a synthetic peptide containing FAK residues 714–730. An inhibitory role for S1 phosphorylation in FAK signalling was indicated by findings that both alanine substitution for S1 and dephosphorylation of S1 by PP1 (serine/threonine protein phosphatase type-1) resulted in an increase in FAK kinase activity; likewise, this role was also shown by cell treatment with the GSK3 inhibitor LiCl. The inhibitory role was confirmed by the finding that cells expressing FAK with alanine substitution for S1 displayed improved cell spreading and faster migration in wound-healing and trans-well assays. Finally, the finding that S1 phosphorylation increased in cells treated with the PP1 inhibitor okadaic acid indicated targeting of this site by PP1. These results indicate an additional mechanism for regulation of FAK activity during cell spreading and migration, involving Ser-722 phosphorylation modulated through the competing actions of GSK3β and PP1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GSK3 takes centre stage more than 20 years after its discovery
FRAME, S., & COHEN, P. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3590001 · Cited by 1,433
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369
Cdc42 regulates GSK-3β and adenomatous polyposis coli to control cell polarity
Etienne-Manneville, S., & Hall, A. (2003) · Nature · doi:10.1038/nature01423 · Cited by 835
Cited by
Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics
Jope, R. S., Yuskaitis, C. J., & Beurel, E. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9128-5 · Cited by 774
“[36].”
GSK-3 as potential target for therapeutic intervention in cancer
McCubrey, J. A., Steelman, L. S., Bertrand, F. E., Davis, N. M., Sokolosky, M., Abrams, S. L., Montalto, G., D’Assoro, A. B., Libra, M., Nicoletti, F., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2037 · Cited by 508
The extended PP1 toolkit: designed to create specificity
Bollen, M., Peti, W., Ragusa, M. J., & Beullens, M. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.03.002 · Cited by 508
GSK-3: Functional Insights from Cell Biology and Animal Models
Kaidanovich-Beilin, O., & Woodgett, J. R. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00040 · Cited by 485
Leaphart, C. L., Cavallo, J., Gribar, S. C., Cetin, S., Li, J., Branca, M. F., Dubowski, T. D., Sodhi, C. P., & Hackam, D. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4808 · Cited by 480
What Are the bona fide GSK3 Substrates?
Sutherland, C. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/505607 · Cited by 345
New concepts regarding focal adhesion kinase promotion of cell migration and proliferation
Cox, B. D., Natarajan, M., Stettner, M. R., & Gladson, C. L. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20956 · Cited by 291
Focal adhesion kinase: A potential target in cancer therapy
van Nimwegen, M. J., & van de Water, B. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.08.011 · Cited by 277
McCubrey, J. A., Steelman, L. S., Bertrand, F. E., Davis, N. M., Abrams, S. L., Montalto, G., D'Assoro, A. B., Libra, M., Nicoletti, F., Maestro, R., et al. (2014) · Leukemia · doi:10.1038/leu.2013.184 · Cited by 255
Yuskaitis, C. J., & Jope, R. S. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2008.10.014 · Cited by 240
Morgan-Smith, M., Wu, Y., Zhu, X., Pringle, J., & Snider, W. D. (2014) · eLife · doi:10.7554/elife.02663 · Cited by 76
Focal adhesion kinase regulates insulin resistance in skeletal muscle
Bisht, B., Goel, H. L., & Dey, C. S. (2007) · Diabetologia · doi:10.1007/s00125-007-0591-6 · Cited by 63
Metadata
- Authors
- Bianchi, M., De Lucchini, S., Marin, O., Turner, D. L., Hanks, S. K., & Villa-Moruzzi, E.
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2005-10-10
- Volume
- 391
- Issue
- 2
- Pages
- 359-370
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W2017079446
- Cited by
- 100
- References
- 3
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.